Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19279 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Ayelet I Rubenstein und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Penn…. Hauptthemen laut MEDLINE: Castleman Disease, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia, Thrombocytosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FDA HHS, NHLBI NIH HHS, EUSA Pharma.
Abstract (Originalsprache)
Idiopathic multicentric Castleman disease (iMCD) is a rare haematological disorder characterized by generalized lymphadenopathy with atypical histopathological features and systemic inflammation caused by a cytokine storm involving interleukin‐6 (IL‐6). Three clinical subtypes are recognized: thrombocytopenia, anasarca, fever, renal dysfunction, organomegaly (iMCD‐TAFRO); idiopathic plasmacytic lymphadenopathy (iMCD‐IPL), involving thrombocytosis and hypergammaglobulinaemia; and iMCD‐not otherwise specified (iMCD‐NOS), which includes patients who do not meet criteria for the other subtypes. Disease pathogenesis is poorly understood, with potential involvement of infectious, clonal and/or autoimmune mechanisms. To better characterize iMCD clinicopathology and gain mechanistic insights into iMCD, we analysed complete blood counts, other clinical laboratory values and blood smear morphology among 63 iMCD patients grouped by clinical subtype. Patients with iMCD‐TAFRO had large platelets, clinical severity associated with lower platelet counts and transfusion‐resistant thrombocytopenia, similar to what is observed with immune‐mediated destruction of platelets in immune thrombocytopenic purpura. Conversely, elevated platelet counts in iMCD‐IPL were associated with elevated IL‐6 and declined following anti‐IL‐6 therapy. Our data suggest that autoimmune mechanisms contribute to the thrombocytopenia in at least a portion of iMCD‐TAFRO patients whereas IL‐6 drives thrombocytosis in iMCD‐IPL, and these mechanisms likely contribute to disease pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Melanie D Mumau, David C Fajgenbaum
Förderung
- FDA HHS
- NHLBI NIH HHS
- EUSA Pharma
- National Heart, Lung, and Blood Institute
- U.S. Food and Drug Administration
- Recordati Rare Diseases
Zitieren
APA
Rubenstein, A. I., Pierson, S. K., Shyamsundar, S., Bustamante, M. S., Gonzalez, M. V., Milller, I. D., Brandstadter, J. D., Mumau, M. D., & Fajgenbaum, D. C. (2024). Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease. British Journal of Haematology. https://doi.org/10.1111/bjh.19279
Vancouver
Rubenstein AI, Pierson SK, Shyamsundar S, Bustamante MS, Gonzalez MV, Milller ID, et al. Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease. British Journal of Haematology. 2024. doi:10.1111/bjh.19279
BibTeX
@article{Rubenstein2024,
author = {Rubenstein, Ayelet I and Pierson, Sheila K and Shyamsundar, Saishravan and Bustamante, Mateo Sarmiento and Gonzalez, Michael V and Milller, Ira D and Brandstadter, Joshua D and Mumau, Melanie D and Fajgenbaum, David C},
title = {Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19279}
}
EUVIMED